Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Inv. presentation
Employment agrmnt
|
|
TITAN PHARMACEUTICALS INC (TTNP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/02/2013 |
8-K
| Amended existing or entered into new employment agreement with an officer |
| 01/04/2012 |
8-K
| Form 8-K - Current report |
| 12/29/2010 |
8-K
| Form 8-K - Current report |
| 06/16/2010 |
8-K
| Amended existing or entered into new employment agreement with an officer|
Docs:
|
"Amendment to Employment Agreement between the registrant and Marc Rubin",
"Amendment to Employment Agreement between the registrant and Sunil Bhonsle",
"PROBUPHINE ® PATENT ISSUED BY THE U.S. PATENT AND TRADEMARK OFFICE South San Francisco, CA - June 16, 2010 - Titan Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has issued patent number 7,736,665 covering Probuphine for the treatment of opiate addiction. Titan is the assignee of this patent which claims a method for treating opiate addiction with a subcutaneously implanted device comprising buprenorphine and ethylene vinyl acetate, a biocompatible copolymer that releases buprenorphine continuously for extended periods of time. This patent, which also includes certain additional claims covering the composition and dimensions of the device, will expire in June 2023 excluding any patent term adjustment which is expected to add several months to t..." |
|
|
|